Cyclin-dependent kinases (CDKs) play a role in cell cycle regulation, and CDK4/6 inhibitors have emerged as therapeutic targets and shown anticancer activity in CRC [20]. The gene discussed is CDK4; the disease is colorectal carcinoma.